UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

190P Observational cohort study of 1st line bevacizumab combined with chemotherapy in metastatic colorectal cancer (HGCSG0802): Sub-group analysis by the Glasgow Prognostic Score (GPS)

Annals of oncology, 2016-12, Vol.27, p.ix59-ix60

2016

Volltextzugriff (PDF)

190P Observational cohort study of 1st line bevacizumab combined with chemotherapy in metastatic colorectal cancer (HGCSG0802): Sub-group analysis by the Glasgow Prognostic Score (GPS)

Annals of oncology, 2016-12, Vol.27 (suppl_9)

2016

Volltextzugriff (PDF)

172PD Final analysis: Phase II trial of irinotecan/S-1/cetuximab (IRIS/Cet) as second line treatment in patients with KRAS exon2 wild type metastatic colorectal cancer: HGCSG0902. Comparison of administration interval in cetuximab treatment

Annals of oncology, 2016-12, Vol.27 (suppl_9)

2016

Volltextzugriff (PDF)

172PD Final analysis: Phase II trial of irinotecan/S-1/cetuximab (IRIS/Cet) as second line treatment in patients with KRAS exon2 wild type metastatic colorectal cancer: HGCSG0902. Comparison of administration interval in cetuximab treatment

Annals of oncology, 2016-12, Vol.27, p.ix54-ix54

2016

Volltextzugriff (PDF)

3521 POSTER Prolongation of survival and improvement of performance status (PS) by chemotherapy in gastrointestinal cancer patients with poor PS

European journal of cancer supplements, 2007, Vol.5 (4), p.265-265

2007

Volltextzugriff (PDF)

162P Updated analysis: Phase II trial of irinotecan plus S-1 (IRIS) with cetuximab (IRIS/Cet) in pre-treated patients with KRAS wild type metastatic colorectal cancer (mCRC): HGCSG0902

Annals of oncology, 2015-12, Vol.26, p.ix42-ix42

2015

Volltextzugriff (PDF)

158P A retrospective cohort study evaluating the safety and efficacy of regorafenib in patients with metastatic colorectal cancer; The HGCSG1401 study -first report

Annals of oncology, 2015-12, Vol.26, p.ix42-ix42

2015

Volltextzugriff (PDF)

P-152 Observational Cohort Study of 1st line Bevacizumab Combined with Chemotherapy in Metastatic Colorectal Cancer (HGCSG0802): Sub-group Analysis by the Glasgow Prognostic Score (GPS)

Annals of oncology, 2016-06, Vol.27, p.ii45

2016

Volltextzugriff (PDF)

P-147 Final analysis: phase II trial of Irinotecan/S-1/cetuximab (IRIS/Cet) as second line treatment in patients with KRAS exon2 wild type mCRC: HGCSG0902. -comparison of administration interval in cetuximab treatment

Annals of oncology, 2016-06, Vol.27, p.ii43

2016

Volltextzugriff (PDF)

538PFIRST REPORT OF A PHASE II TRIAL OF IRINOTECAN PLUS S-1 (IRIS) WITH CETUXIMAB (IRIS/CET) IN PRE-TREATED PATIENTS WITH KRAS WILD TYPE OF METASTATIC COLORECTAL CANCER (MCRC): HGCSG0902

Annals of oncology, 2014-09, Vol.25 (suppl_4), p.iv183-iv184

2014

Volltextzugriff (PDF)

First Report of a Phase Ii Trial of Irinotecan Plus S-1 (Iris) with Cetuximab (Iris/Cet) in Pre-Treated Patients with Kras Wild Type of Metastatic Colorectal Cancer (Mcrc): Hgcsg0902

Annals of oncology, 2014-09, Vol.25, p.iv183

2014

Volltextzugriff (PDF)

P-269 Phase II trial of Irinotecan/S-1 (IRIS) with Cetuximab (IRIS/Cet) as second line treatment in patients with KRAS WT metastatic colorectal cancer: HGCSG0902. -Comparison of administration interval in Cetuximab treatment

Annals of oncology, 2015-06, Vol.26, p.iv79

2015

Volltextzugriff (PDF)

P-271 Retrospective Cohort Study on the Safety and Efficacy of Regorafenib for Metastatic Colorectal Cancer Patients: The HGCSG1401 Study -First Report

Annals of oncology, 2015-06, Vol.26, p.iv80

2015

Volltextzugriff (PDF)

Safety Report of a Phase II Trial of Irinotecan Plus S-1 (Iris) with Cetuximab in Pre-Treated Patients with KRAS Wild Type of Metastatic Colorectal Cancer: HGCSG0902

Annals of oncology, 2012-10, Vol.23, p.xi87

2012

Volltextzugriff (PDF)

What can we do for gastrointestinal cancer patients with poor performance status (PS)?

Journal of clinical oncology, 2007-06, Vol.25 (18_suppl), p.19629-19629

2007

Volltextzugriff (PDF)

Metastatic Rectal Cancer Responding to Third-line Therapy Employing Bevacizumab After Failure of Oxaliplatin and Irinotecan: Case Report

Japanese journal of clinical oncology, 2008-07, Vol.38 (7), p.493-496

2008

Volltextzugriff (PDF)

Disturbance of the Growth Hormone–Insulin-like Growth Factor-1 Axis Associated with Poor Performance Status in Patients with Solid Tumors

Japanese journal of clinical oncology, 2010-03, Vol.40 (3), p.222-226

2010

Volltextzugriff (PDF)

Hepatic Arterial Infusion of Oxaliplatin for a Patient with Hepatic Metastases from Colon Cancer Undergoing Hemodialysis

Japanese journal of clinical oncology, 2007-07, Vol.37 (7), p.540-543

2007

Volltextzugriff (PDF)

Expression of the serotonin transporter SERT in the genital tract of cattle

Regulatory peptides, 2009, Vol.154 (1-3), p.1-4

2009

Volltextzugriff (PDF)

HGF/SF-INDUCED SPREADING OF MDCK CELLS CORRELATES WITH DISAPPEARANCE OF BARMOTIN/7H6, A TIGHT JUNCTION-ASSOCIATED PROTEIN, FROM THE CELL MEMBRANE

Cell biology international, 2000-01, Vol.24 (7), p.439-446

2000

Volltextzugriff (PDF)

Surface hydrogen processes studied by isotope exchange reactions on a Pd membrane cathode

Journal of electroanalytical chemistry (Lausanne, Switzerland), 1996-01, Vol.401 (1), p.81-87

1996

Volltextzugriff (PDF)

Antibacterial Activity of Pectin Hydrolyzates

Nippon Shokuhin Kōgyō Gakkaishi, 1994, Vol.41 (11), p.785-792

1994

Volltextzugriff (PDF)

A Clinical Study of 106 Cases of Colorectal Carcinoma Associated with Other Primary Malignancies

Nippon Daicho Komonbyo Gakkai Zasshi, 1996, Vol.49(3), pp.207-212

1996

Volltextzugriff (PDF)

W.J. Ashley as a Candidate for the Drummond Professorship of Political conomy in the University of Oxford

SOCIO-ECONOMIC HISTORY, 1931/05/10, Vol.1(1), pp.165-224

Muto, O.

1931

Volltextzugriff (PDF)

Photochemical reaction of 7,8-dihydrorhodopsin at low temperatures

Biochimica et biophysica acta, 1984-09, Vol.766 (3), p.597-602

1984

Volltextzugriff (PDF)

26 – 50 von 686

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(553)
Mit Volltextzugriff
(535)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

4 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(312)
Humans
(167)
Life Sciences & Biomedicine
(156)
Physical Sciences
(137)
Physics
(124)
Male
(93)
Female
(91)
Biological And Medical Sciences
(81)
Middle Aged
(76)
Medical Sciences
(74)
Exact Sciences And Technology
(69)
Aged
(59)
Adult
(52)
Animals
(52)
Physics, Fluids & Plasmas
(46)
Surgery
(44)
Oncology
(37)
Technology
(32)
Tumors
(31)
Gastroenterology. Liver. Pancreas. Abdomen
(30)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(3)
... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

190P Observational cohort study of 1st line bevacizumab combined with chemotherapy in metastatic colorectal cancer (HGCSG0802): Sub-group analysis by the Glasgow Prognostic Score (GPS)

190P Observational cohort study of 1st line bevacizumab combined with chemotherapy in metastatic colorectal cancer (HGCSG0802): Sub-group analysis by the Glasgow Prognostic Score (GPS)

172PD Final analysis: Phase II trial of irinotecan/S-1/cetuximab (IRIS/Cet) as second line treatment in patients with KRAS exon2 wild type metastatic colorectal cancer: HGCSG0902. Comparison of administration interval in cetuximab treatment

172PD Final analysis: Phase II trial of irinotecan/S-1/cetuximab (IRIS/Cet) as second line treatment in patients with KRAS exon2 wild type metastatic colorectal cancer: HGCSG0902. Comparison of administration interval in cetuximab treatment

3521 POSTER Prolongation of survival and improvement of performance status (PS) by chemotherapy in gastrointestinal cancer patients with poor PS

162P Updated analysis: Phase II trial of irinotecan plus S-1 (IRIS) with cetuximab (IRIS/Cet) in pre-treated patients with KRAS wild type metastatic colorectal cancer (mCRC): HGCSG0902

158P A retrospective cohort study evaluating the safety and efficacy of regorafenib in patients with metastatic colorectal cancer; The HGCSG1401 study -first report

P-152 Observational Cohort Study of 1st line Bevacizumab Combined with Chemotherapy in Metastatic Colorectal Cancer (HGCSG0802): Sub-group Analysis by the Glasgow Prognostic Score (GPS)

P-147 Final analysis: phase II trial of Irinotecan/S-1/cetuximab (IRIS/Cet) as second line treatment in patients with KRAS exon2 wild type mCRC: HGCSG0902. -comparison of administration interval in cetuximab treatment

538PFIRST REPORT OF A PHASE II TRIAL OF IRINOTECAN PLUS S-1 (IRIS) WITH CETUXIMAB (IRIS/CET) IN PRE-TREATED PATIENTS WITH KRAS WILD TYPE OF METASTATIC COLORECTAL CANCER (MCRC): HGCSG0902

First Report of a Phase Ii Trial of Irinotecan Plus S-1 (Iris) with Cetuximab (Iris/Cet) in Pre-Treated Patients with Kras Wild Type of Metastatic Colorectal Cancer (Mcrc): Hgcsg0902

P-269 Phase II trial of Irinotecan/S-1 (IRIS) with Cetuximab (IRIS/Cet) as second line treatment in patients with KRAS WT metastatic colorectal cancer: HGCSG0902. -Comparison of administration interval in Cetuximab treatment

P-271 Retrospective Cohort Study on the Safety and Efficacy of Regorafenib for Metastatic Colorectal Cancer Patients: The HGCSG1401 Study -First Report

Safety Report of a Phase II Trial of Irinotecan Plus S-1 (Iris) with Cetuximab in Pre-Treated Patients with KRAS Wild Type of Metastatic Colorectal Cancer: HGCSG0902

What can we do for gastrointestinal cancer patients with poor performance status (PS)?

Metastatic Rectal Cancer Responding to Third-line Therapy Employing Bevacizumab After Failure of Oxaliplatin and Irinotecan: Case Report

Disturbance of the Growth Hormone–Insulin-like Growth Factor-1 Axis Associated with Poor Performance Status in Patients with Solid Tumors

Hepatic Arterial Infusion of Oxaliplatin for a Patient with Hepatic Metastases from Colon Cancer Undergoing Hemodialysis

Expression of the serotonin transporter SERT in the genital tract of cattle

HGF/SF-INDUCED SPREADING OF MDCK CELLS CORRELATES WITH DISAPPEARANCE OF BARMOTIN/7H6, A TIGHT JUNCTION-ASSOCIATED PROTEIN, FROM THE CELL MEMBRANE

Surface hydrogen processes studied by isotope exchange reactions on a Pd membrane cathode

Antibacterial Activity of Pectin Hydrolyzates

A Clinical Study of 106 Cases of Colorectal Carcinoma Associated with Other Primary Malignancies

W.J. Ashley as a Candidate for the Drummond Professorship of Political conomy in the University of Oxford

Photochemical reaction of 7,8-dihydrorhodopsin at low temperatures

Suchergebnisse filtern